Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Harvey, Illinois Clinical Trials

A listing of Harvey, Illinois clinical trials actively recruiting patient volunteers.

RESULTS

Found (10) clinical trials

The objective of this study is to describe the occurrence of AEs leading to dose reduction following afatinib treatment in NSCLC patients with common EGFR mutations (Deletion 19 and/or L858R) who are 70 years of age or older.

Phase

0.0 miles

Learn More »

INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure

Influenza leads to significant morbidity and mortality, particularly in patients with cardiovascular disease. Influenza-related death is more common in patients with cardiovascular disease than any other chronic health condition. Influenza infection has been temporally associated with acute cardiovascular events, such as acute coronary syndrome and acute heart failure. Due to ...

Phase

3.0 miles

Learn More »

Dapagliflozin in PRESERVED Ejection Fraction Heart Failure

A 12-week randomized, double-blind, placebo-controlled trial to evaluate the effects of once-daily dapagliflozin 10 mg on heart failure disease-specific biomarkers (NTproBNP and BNP), symptoms, health status, and quality of life in patients with chronic heart failure with preserved systolic function. An imaging substudy will also be conducted to explore the ...

Phase

3.27 miles

Learn More »

A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod

A study of immune phenotype biomarkers in patients with Relapsing Multiple Sclerosis (RMS) after treatment with 0.5mg fingolimod

Phase

4.89 miles

Learn More »

A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects

GlaxoSmithKline (GSK) in collaboration with Propeller Health has developed a sensor, which can clip on to the ELLIPTA dry powder inhaler (DPI) and monitor the time and date that the ELLIPTA DPI cover is fully opened and closed. Additionally, a sensor will be attached to the rescue medication metered dose ...

Phase

4.89 miles

Learn More »

Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use

This study will evaluate the efficacy and safety of eluxadoline 100 milligrams (mg) twice a day (BID) versus placebo for the treatment of patients with Irritable Bowel Syndrome with Diarrhea (IBS-D) who report that the use of loperamide in the prior 12 months failed to provide control of their IBS-D ...

Phase

8.12 miles

Learn More »

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE )

This is a blinded and placebo-controlled study of topical testosterone replacement therapy (TRT) in symptomatic hypogonadal men with increased risk for cardiovascular (CV) disease.

Phase

8.12 miles

Learn More »

Effects of Sacubitril/Valsartan Therapy on Biomarkers Myocardial Remodeling and Outcomes.

This study is to determine early and more chronic changes in concentrations of biomarkers related to mechanisms of action (MOA) and effects of sacubitril/valsartan therapyover a period of 12 months, and correlate these biomarker changes with cardiac remodeling parameters, patient-reported outcomes and cardiovascular outcomes.

Phase

8.79 miles

Learn More »

Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy

Data from a previous single arm study (RESPITE) indicate that transition from PDE5i to riociguat may be feasible, safe and beneficial in patients not adequately responding to PDE5i. REPLACE is a randomized controlled study to confirm the potential clinical benefit of transition from PDE5i to riociguat. Satisfactory clinical response in ...

Phase

8.79 miles

Learn More »

EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)

Patients with advanced heart failure with reduced ejection fraction (HFrEF) have extremely high morbidity and mortality with 1 year outcomes of death and hospitalization of approximately 50%. For the most advanced heart failure patients, the evidence base for medical treatment is limited with consensus guidelines recommending consideration for either cardiac ...

Phase

8.79 miles

Learn More »